Trial Profile
A Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 Months of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.
- 16 May 2019 This trial has been completed in Norway as per European Clinical Trials Database record.
- 05 May 2011 Results published in the Pediatric Infectious Disease Journal.
- 29 Oct 2009 Results were presented at IDSA 2009.